HAMLET B — Hamlet BioPharma AB Cashflow Statement
0.000.00%
- SEK746.28m
- SEK726.25m
Annual cashflow statement for Hamlet BioPharma AB, fiscal year end - June 30th, SEK millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -23.4 | -7.72 | -17.2 | -20.4 | -41.8 |
Non-Cash Items | 0.036 | 0.261 | 0.009 | 0.499 | 7.83 |
Other Non-Cash Items | |||||
Changes in Working Capital | 0.145 | 1.69 | -3.13 | 0.329 | -2.02 |
Change in Accounts Receivable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -23.3 | -5.77 | -20.3 | -19.6 | -36 |
Capital Expenditures | — | — | — | -9.97 | -0.278 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Cash from Investing Activities | — | — | — | -9.97 | -0.278 |
Financing Cash Flow Items | -0.026 | 0 | -3.66 | -0.132 | -0.779 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 25.9 | 0 | 52.5 | 8.37 | 41 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.62 | -5.77 | 32.1 | -21.2 | 4.71 |